Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
About Centogene N.V.
Centogene N.V. (Nasdaq: CNTG) is a global leader in the field of genetic diagnostics and multiomic testing services, specializing in rare and neurodegenerative diseases. Founded in 2006, the company has carved a niche in the life sciences industry by integrating advanced sequencing technologies with a robust biodatabank to provide data-driven insights that enable precise diagnosis, drug discovery, and development. Centogene's mission is to deliver life-changing answers to patients, physicians, and pharmaceutical companies worldwide, addressing unmet needs in the healthcare ecosystem.
Core Business Areas
Centogene operates across three primary domains:
- Diagnostics: The company offers a comprehensive portfolio of over 5,000 genetic and biochemical tests, including whole exome sequencing (WES), whole genome sequencing (WGS), and biomarker analyses. Its diagnostic solutions cover more than 19,000 genes, enabling early and accurate detection of over 2,500 rare diseases.
- Biodatabank: At the heart of Centogene's operations is its proprietary CENTOGENE Biodatabank, the world's largest real-world integrated multiomic data repository for rare and neurodegenerative diseases. This database includes over 850,000 patient samples from more than 120 countries, with a significant representation of non-European populations, making it a critical resource for understanding genetic diversity.
- Pharmaceutical Partnerships: Centogene collaborates with leading pharmaceutical companies to accelerate drug discovery and development. By leveraging its biodatabank and multiomic expertise, the company de-risks and expedites the clinical development of targeted therapies, particularly for orphan and neurodegenerative diseases.
Competitive Advantage
Centogene's competitive edge lies in its unique integration of diagnostics, data analytics, and pharmaceutical collaboration. The CENTOGENE Biodatabank serves as a cornerstone for its operations, enabling the identification of novel genetic variants and biomarkers. This data-driven approach not only facilitates accurate diagnostics but also supports the development of precision medicine solutions. Additionally, the company's partnerships with global pharmaceutical giants like Takeda and Evotec underscore its role as a trusted partner in the life sciences industry.
Market Significance
Operating at the intersection of healthcare and biotechnology, Centogene addresses critical gaps in the diagnostics and treatment of rare diseases. Its contributions extend beyond individual patient care to advancing global health insights through its extensive research and development efforts. The company's work has led to over 300 peer-reviewed publications, highlighting its commitment to scientific excellence and innovation.
Collaborative Ecosystem
Centogene's collaborative model includes partnerships with pharmaceutical companies, academic institutions, and healthcare providers. These collaborations focus on accelerating the development of novel therapies, improving patient outcomes, and expanding access to genetic testing. Notable initiatives include the ROPAD Study, which explores the genetic underpinnings of Parkinson's disease, and partnerships aimed at addressing lysosomal storage disorders and other rare conditions.
Future Outlook
With a steadfast commitment to innovation and patient-centric solutions, Centogene is poised to continue its leadership in the genetic diagnostics landscape. By integrating cutting-edge technologies with real-world data, the company aims to transform the diagnosis and treatment of rare and neurodegenerative diseases, ultimately contributing to a world healed of these conditions.
Centogene N.V. (Nasdaq: CNTG) announced that CEO Andrin Oswald, M.D., is on a temporary medical leave for at least four weeks. Kim Stratton has been named Interim CEO, bringing over 25 years of biopharmaceutical experience. The Board expressed confidence in the management team during this transition. Centogene focuses on rare diseases, leveraging a proprietary platform with data on over 600,000 patients globally. This platform aims to enhance the understanding of hereditary diseases and accelerate orphan drug development.
Centogene (Nasdaq: CNTG) reported Q3 2021 revenues of €30.2 million, down 17% from €36.3 million in Q3 2020. The Diagnostics segment saw a 43% revenue increase to €7.3 million, while Pharma revenues fell 28% to €2.7 million. COVID-19 testing revenues decreased to €20.2 million. The company is restructuring to phase out COVID-19 testing and plans to cut costs by up to €15 million annually. Cash reserves declined to €25.7 million. Centogene is optimistic about future growth in its Core Business, expecting 30-40% overall revenue growth for FY2021.
Centogene N.V. (Nasdaq: CNTG) announced it will release its financial results for Q3 2021 on November 24, 2021, at 2 p.m. CET / 8 a.m. ET. A conference call and webcast will follow to discuss these results. Participants can register in advance to receive dial-in numbers and passcodes. The company specializes in rare diseases, utilizing a unique platform with over 3.9 billion data points from 600,000 patients globally. Centogene aims to enhance diagnosis and treatment through extensive research and collaboration with over 30 pharmaceutical partners.
Centogene has expanded its partnership with Agios Pharmaceuticals to provide genetic testing and clinical trial support for pivotal studies in thalassemia and sickle cell disease. This three-year fee-for-service agreement enhances access to genetic testing for patients globally, utilizing Centogene's proprietary CentoCard® for analysis. The collaboration aims to improve understanding of these rare diseases and advance Agios' PK activator therapy, addressing unmet needs in treatment options. Centogene's extensive rare disease Bio/Databank supports this initiative.
Centogene N.V. (Nasdaq: CNTG) has announced the enrollment of the first patient in the EFRONT Study, focusing on frontotemporal dementia (FTD). This observational study aims to assess the prevalence of genetic mutations in over 3,000 FTD patients across seven countries, leveraging Centogene's extensive Bio/Databank. Currently, there are no FDA-approved treatments for FTD, which affects many under 65. Patients with the progranulin gene mutation may join Alector’s Phase 3 INFRONT-3 trial for a potential new treatment. This initiative aligns with Centogene’s goal to address 100 rare diseases in the next decade.
Centogene (Nasdaq: CNTG) and Twist Bioscience (Nasdaq: TWST) announced a collaboration to develop custom assay kits for diagnosing rare diseases. This partnership aims to enhance genetic testing accessibility and increase understanding of rare conditions. By combining Centogene's extensive database, which includes over 3.9 billion data points and insights from 600,000 patients, with Twist's advanced DNA synthesis technology, the collaboration seeks to improve the precision of rare disease diagnostics and potentially lead to novel therapeutic discoveries. Financial terms of the agreement remain undisclosed.
Twist Bioscience Corporation (TWST) and Centogene N.V. (CNTG) have partnered to develop custom assay kits targeting the diagnosis of rare diseases. This collaboration aims to enhance genetic testing accessibility for patients, ultimately improving understanding and treatment of rare conditions. Although no financial details were disclosed, the partnership seeks to utilize Centogene's extensive Bio/Databank and Twist's DNA synthesis technologies. The initiative is part of Centogene's goal to drive insights and potentially cure up to 100 rare diseases within the next decade.
Centogene (Nasdaq: CNTG) announced a major breakthrough in treating structural birth defects in a recent global genetic study published in the New England Journal of Medicine. Utilizing data from over 20,000 families, researchers identified genetic variations in the WLS gene linked to these defects. A pharmacologic Wnt agonist was able to restore embryonic development in preclinical models. This study marks a significant step toward developing targeted therapies for 4 million infants affected by birth defects annually, highlighting Centogene's commitment to curing 100 rare diseases within the next decade.
Centogene N.V. (Nasdaq: CNTG) reported strong Q2 2021 results, achieving revenues of €51.9 million, a 434% increase from €9.7 million in Q2 2020. The firm highlighted a 25% rise in revenues from its core Pharma and Diagnostics segments, with Clinical Diagnostics growing 82% to €6.7 million. Significant COVID-19 testing revenues of €42.3 million contributed to overall earnings. However, Pharma revenues declined to €2.8 million. With a focus on rare diseases, Centogene aims to enable cures for 100 rare diseases in the next decade, driven by the growth of its Bio/Databank and new executive appointments.
Centogene N.V. (Nasdaq: CNTG) announced that it will release its financial results for the quarter ending June 30, 2021, on September 7, 2021. A conference call and webcast will follow at 2 p.m. CEST / 8 a.m. EDT to discuss these results. Centogene focuses on rare diseases, utilizing a vast global data platform comprising over 3.9 billion data points from approximately 600,000 patients across 120 countries to enhance diagnosis and treatment. The firm collaborates with over 30 pharmaceutical partners to drive orphan drug development.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is the CENTOGENE Biodatabank?
How does Centogene collaborate with pharmaceutical companies?
What types of tests does Centogene offer?
What makes Centogene unique in the diagnostics market?
What diseases does Centogene focus on?
Who are Centogene's key collaborators?
What is the ROPAD Study?
